-
The vernakalant story: how did it come to approval in Europe and what is the delay in the U.S.A?
Current cardiology reviews 20141101
-
Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20140201
-
Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
Vascular health and risk management 20130101
-
[New antiarrhythmic drugs for the treatment of atrial fibrillation].
Giornale italiano di cardiologia (2006) 20121001
-
Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter.
Journal of clinical pharmacology 20120701
-
Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity.
Expert opinion on drug safety 20120701
-
Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20120601
-
All that glitters..
Prescrire international 20120501
-
Vernakalant. Too dangerous in atrial fibrillation.
Prescrire international 20120501
-
Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol.
Circulation. Arrhythmia and electrophysiology 20120401
-
Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation.
Cardiovascular drugs and therapy 20120401
-
Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations.
Heart rhythm 20120301
-
Comparative pharmacophysiology of vernakalant, ranolazine, and d-sotalol in canine pulmonary vein sleeve preparations: new flavors or same old taste?
Heart rhythm 20120301
-
[Emergency medicine: updates 2011].
Revue medicale suisse 20120111
-
[The AVRO study].
Giornale italiano di cardiologia (2006) 20111101
-
Update on the management of atrial fibrillation: anticoagulation and medical therapy.
Current cardiology reports 20111001
-
Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.
Journal of pharmacokinetics and pharmacodynamics 20111001
-
A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
Circulation. Arrhythmia and electrophysiology 20111001
-
The novel Kv1.5 channel blocker vernakalant for successful treatment of new-onset atrial fibrillation in a critically ill abdominal surgical patient.
British journal of anaesthesia 20111001
-
[New concepts in the therapy of atrial fibrillation].
Deutsche medizinische Wochenschrift (1946) 20110801
-
Atrial selective effects of intravenously administered vernakalant in conscious beagle dogs.
Journal of cardiovascular pharmacology 20110701
-
Antiarrhythmic drugs for atrial fibrillation.
Expert opinion on pharmacotherapy 20110601
-
Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.
Drugs & aging 20110601
-
[Vernakalant--a new drug for pharmacological conversion of atrial fibrillation].
Medizinische Monatsschrift fur Pharmazeuten 20110501
-
Comparison of the in vivo hemodynamic effects of the antiarrhythmic agents vernakalant and flecainide in a rat hindlimb perfusion model.
Journal of cardiovascular pharmacology 20110401
-
Disposition and mass balance of [14C]vernakalant after single intravenous and oral doses in healthy volunteers.
Drug metabolism letters 20110401
-
Vernakalant selectively prolongs atrial refractoriness with no effect on ventricular refractoriness or defibrillation threshold in pigs.
Journal of cardiovascular pharmacology 20110301
-
The pharmaceutical pipeline for atrial fibrillation.
Annals of medicine 20110201
-
Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
Drugs 20110122
-
A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
Journal of the American College of Cardiology 20110118
-
Vernakalant: additional evidence for safety and efficacy for new onset atrial fibrillation.
Journal of the American College of Cardiology 20110118
-
Vernakalant: a new drug to treat patients with acute onset atrial fibrillation.
Cardiology in review 20110101
-
Novel agents for the acute conversion of atrial fibrillation: focus on vernakalant.
Recent patents on cardiovascular drug discovery 20110101
-
[Update on current care guidelines: atrial fibrillation].
Duodecim; laaketieteellinen aikakauskirja 20110101
-
[New developments in the antiarrhythmic therapy of atrial fibrillation].
Herzschrittmachertherapie & Elektrophysiologie 20101201
-
Vernakalant.
Nature reviews. Drug discovery 20101201
-
Advances in the treatment of atrial fibrillation.
Minerva cardioangiologica 20101201
-
Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
The American journal of cardiology 20101101
-
Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department.
Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 20101101
-
Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
Current opinion in investigational drugs (London, England : 2000) 20100901
-
Vernakalant: A novel agent for the termination of atrial fibrillation.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100715
-
A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
American heart journal 20100601
-
[Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].
Deutsche medizinische Wochenschrift (1946) 20100501
-
New antiarrhythmic drugs for treatment of atrial fibrillation.
Lancet (London, England) 20100403
-
[Ionic mechanisms of action of class III antiarrhythmic drugs].
Kardiologiia 20100101
-
[New antiarrhythmic drugs for treatment of atrial fibrillation].
Duodecim; laaketieteellinen aikakauskirja 20100101
-
Vernakalant hydrochloride for the treatment of atrial fibrillation.
Expert opinion on investigational drugs 20091201
-
Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
Circulation. Arrhythmia and electrophysiology 20091201
-
Modeling of high-affinity binding of the novel atrial anti-arrhythmic agent, vernakalant, to Kv1.5 channels.
Journal of molecular graphics & modelling 20091001
-
New pharmacological agents for arrhythmias.
Circulation. Arrhythmia and electrophysiology 20091001
-
Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
Journal of clinical pharmacology 20090101
-
Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?
Current opinion in cardiology 20090101
-
New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant.
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 20081001
-
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits?
The American journal of cardiology 20080922
-
Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.
Expert opinion on investigational drugs 20080501
-
Vernakalant: pharmacology electrophysiology, safety and efficacy.
Drugs of today (Barcelona, Spain : 1998) 20080501
-
Vernakalant in the management of atrial fibrillation.
The Annals of pharmacotherapy 20080401
-
Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.
Circulation 20080325
-
The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels.
Molecular pharmacology 20071201
-
The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans.
Journal of cardiovascular pharmacology 20070701
-
Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent.
Expert opinion on investigational drugs 20070401